INVESTOR RELATIONS
Our Goal – Confidence and Common Success
It is our firm wish to maintain an open and honest relationship between potential investors, share holders and Bachem. We inform transparently and consequently about all relevant facts; according to our internal guidelines and all statutory laws and guidelines. Investor Relations has to prepare and provide this information in a timely, correct and meaningful manner. We want to ensure that our shareholders and potential investors get a reliable picture of the Bachem Group in terms of the current situation and expected future developments. We aim to achieve a basis of trust on which we can build and maintain long term and successful relationships. We are looking forward to working with you.
In Dialog with Bachem
We stay in contact and dialog with our investors through the following channels:
- Our annual general meeting
- Our half-year and annual report
- Press and media releases
- Visits at our site in Bubendorf
- Roadshows and investor relations events
- Individual contacts, personally or by phone
About Bachem
The Swiss based Bachem Group is a public, innovation-driven company specializing in the
development and manufacturing of pepTides and oligonucleoTides. As a full service provider
Bachem offers products for clinical development and commercial applications as well as a
comprehensive catalog and exclusive custom synthesis. With 50 years of experience and
subsidiaries in Switzerland, the United States, the United Kingdom and Japan, Bachem is the
partner of choice for the biotech and pharma industry worldwide.
Bachem. Leading Partner in Tides